Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5851711 | 0.98 | ACACB (0.34) | ACACBMAPTMEN1TSHRKMT2A | |
| SCHEMBL5648274 | 0.80 | TERT (0.37) | MAPTMEN1KMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL4666324 | 0.79 | TERT (0.36) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL22383958 | 0.78 | ALDH1A1 (0.39) | ECE1 | |
| SCHEMBL22062457 | 0.78 | ALDH1A1 (0.39) | ECE1 | |
| SCHEMBL7725268 | 0.78 | MEN1 (0.43) | ACACBMAPTMEN1TSHRKMT2A | |
| SCHEMBL16330362 | 0.76 | TGFBR1 (0.37) | ACACBMAPTCA12CA1CA9 | |
| SCHEMBL5647312 | 0.76 | CTSC (0.38) | ACACBMEN1TSHRKMT2ACA12 | |
| SCHEMBL14813124 | 0.76 | ACACB (0.40) | ACACBMAPTMEN1KMT2ACTSK | |
| SCHEMBL1905479 | 0.76 | CYP2C9 (0.46) | ACACBMAPTMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | claimed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | claimed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166717-A1 | Hydroxy alkyl amines | PSEN1, MAOA, PSEN2 | ACACB 788/4885MAPT 112/4885MEN1 1651/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | ACACB 626/4885MAPT 91/4885MEN1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.